Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00228514 |
Recruitment Status :
Completed
First Posted : September 29, 2005
Last Update Posted : November 15, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rosuvastatin Heart Failure Positron Emission Tomography (PET) | Drug: Rosuvastatin Procedure: Positron emission tomography | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study |
Study Start Date : | February 2004 |
Actual Study Completion Date : | July 2007 |

- Drug: Rosuvastatin
Other Name: Crestor
- Procedure: Positron emission tomography
- To study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve). Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.
- To study the effect of rosuvastatin in Chronic Heart Failure on mismatch. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.
Exclusion Criteria:
- See above

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00228514
Netherlands | |
Research Site | |
Groningen, Netherlands |
Study Director: | AstraZeneca CV Medical Department | AstraZeneca BV |
ClinicalTrials.gov Identifier: | NCT00228514 |
Other Study ID Numbers: |
4522IL/0098 Dutch SubStudy D3562C00098 |
First Posted: | September 29, 2005 Key Record Dates |
Last Update Posted: | November 15, 2010 |
Last Verified: | November 2010 |
Heart Failure Heart Diseases Cardiovascular Diseases Rosuvastatin Calcium Anticholesteremic Agents Hypolipidemic Agents |
Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |